metaEvidence - overview


			deaths (OS)
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
versus ipilimumab alone
	nivolumab alone vs. ipilimumab alone	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	nivolumab plus ipilimumab vs. ipilimumab alone	2	NaN [NaN; NaN] /10000 0/0 vs. 0/0
versus ipilimumab followed by nivolumab
	nivolumab followed by ipilimumab vs. ipilimumab followed by nivolumab	1	-2185 [-3808; -562] /10000 24/68 vs. 40/70
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	relatlimab plus nivolumab vs. nivolumab alone	1	-
versus Standard of Care (SoC)
	tremelimumab vs. Standard of Care (SoC)	1	-361 [-960; 239] /10000 260/328 vs. 271/327